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The objective was to identify predictors of cognitive decline in patients with hypoxaemic COPD on continuous 
oxygen therapy. 
Eighty-four consecutive ambulatory hypoxaemic COPD patients in stable clinical conditions were prospectively 
studied over the course of 2 yr. Baseline multidimensional assessment included respiratory function tests, blood gas 
analysis, Mini Mental Status (MMS) test, Geriatric Depression Scale (GDS), Activities of Daily Living (ADLs) and 
Charlson’s index of comorbidity. Reassessments were made 1 yr and 2 yr thereafter. Sequential changes in MMS, 
GDS and ADLs were assessed by Friedman’s ANOVA by rank test. 
Forty patients completed the study (group A), while 44 died or were lost to follow-up (group B). Group B was 
characterized by more severe respiratory function impairment and worse performances on ADLs and GDS. In 
group A, MMS deteriorated from baseline to the 1 yr and 2 yr reassessments (27 f 2.9 vs. 25.8 i 4.1 and 25.4 & 4, 
P<O.O05), whereas GDS and ADLs did not change significantly; the 23 patients experiencing a decline of MMS had 
baseline lower percentage predicted FVC (52.3 & 17.1 vs. 66.9 f 13.4, PcO.03) and FEVi (27.2 + 8.6 vs. 44 & 26.8, 
PcO.02) values and better affective status (GDS score: 11.9 & 7.7 vs. 16.5 & 5.6, WO.04). Two-year changes in MMS 
and in GDS scores were inversely correlated (Spearman’s p= - 0.32, P=O.O4). 
Cognitive decline is faster in the presence of severe bronchial obstruction and parallels the worsening of the 
affective status in COPD patients on oxygen therapy. The onset of depression rather than baseline depressive 
symptoms seems to be a risk factor for cognitive decline. 
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Introduction 
A strong relationship is known to link COPD and cognitive 
dysfunction. Impairment of several neuropsychological 
functions characterizes hypoxaemic COPD and is partially 
reversible with the oxygen therapy (l-3). Both defective 
retrieval and inaccurate recognition affect verbal memory 
of COPD patients (4). Furthermore, a cross-sectional study 
showed that peak expiratory flow rate was positively associ- 
ated with performance on three screening cognitive tests in 
3812 old men residing in East Boston (5). A recent longitu- 
dinal study correlating midlife pulmonary function with 
late-life cognitive function demonstrated that depressed 
FEV, was an independent predictor of cognitive dysfunc- 
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tion diagnosed by a screening instrument 23 yr after 
respiratory function tests had been performed (6). 
No information is available regarding the rate of decline 
of cognitive function in COPD. The indirect evidence from 
case series studies is consistent with a strong relationship 
existing between length of history of COPD and neuro- 
psychological impairment (3). Arterial hypercapnia 
characterizes patients with severe cognitive dysfunction (7). 
However, comorbid diseases, limitations in social activities 
and depression, which are very common in COPD 
patients, can per se affect cognition (2). Attempts should be 
made to disentangle the effects of these conditions 
on mental status and to identify predictors, if any, of 
cognitive decline. 
The present study aims (1) to assess comparatively 
over the course of 2 yr changes in cognitive, affective 
and functional status of hypoxaemic COPD patients 
without clinically significant cognitive impairment at base- 
line and (2) to characterize subjects at risk of cognitive 
decline. 
0 1998 W. B. SAUNDERS COMPANY LTD 
528 R. ANTONELLI INCALZI ET AL. 
Subjects and Method 
PATIENTS 
All the COPD patients listed in the oxygen therapy register 
of the Pneumology outpatient department of a university 
hospital in October 1993 were requested to participate in 
the study. The study protocol was in accord with guidelines 
provided by the ethics committee of the university. 
The diagnosis of COPD conformed with criteria of the 
American Thoracic Society (8). Sixty-eight patients were on 
continuous oxygen therapy because they had PaO, inferior 
to 7.3 kPa. Ischaemic heart disease coexisting with COPD 
was the rationale for prescribing continuous oxygen 
therapy to the remaining 16 patients, although their PaO, 
ranged from 7.3 to 8.7 kPa. Patients inspired an oxygen- 
enriched mixture through a Ventimask; the inspired con- 
centration of oxygen ranged from 24% to 31% as required 
to obtain SaO,>90%. During ambulation, most of the 
patients inhaled oxygen through nasal prongs at a flow 
ranging between 1 and 4 1 min - ’ as required to achieve 
SaO, 2 90%; the optimal oxygen flow had been previously 
defined by performing a 12 min walking test. Liquid oxygen 
was used; a stroller containing 1000 1 was available during 
ambulation. Compliance with oxygen therapy was checked 
by analysing records of oxygen use written by the patient 
and his or her caregivers. Patients using oxygen for less 
than 19 h were considered to be uncompliant with oxygen 
therapy. This threshold was chosen because using oxygen 
for at least 19 h is known to halve mortality when 
compared with nocturnal oxygen therapy (9). 
All the patients lived at home and were ambulant at the 
time of recruitment and in stable conditions. They regularly 
attended the Pneumology ambulatory every 4 months. 
Criteria for exclusion from the study were as follows: 
dementia, major depressive syndrome or psychiatric 
disorders according to DSMIII-r criteria (10); sensory 
impairment or illiteracy preventing neuropsychological 
assessment; comorbid diseases, e.g. cerebrovascular disease 
or hypothyroidism, apt to affect cognitive function (11); 
bereavement or change in living location in the year before 
recruitment. Patients recognized to be uncompliant with 
oxygen therapy were excluded from the follow-up and were 
considered to be drop-outs. Indeed, regular continuous 
oxygen therapy is known to slow cognitive, affective and 
functional decline, so that lack of compliance with oxygen 
therapy would be a confounding factor (9). 
Patients were provided with a standardized therapy 
including inhaled salbutamol 200 pg t.i.d. and ipratropium 
bromide 250,ug t.i.d. with beclometasone dipropionate 
250,~g t.i.d. added every other month. Nine patients were 
on continuous low-dose steroid therapy per OS (prednisone, 
5 mg daily). Exacerbations of COPD severe enough 
to require hospitalization were treated by parenteral 
antibiotics and steroids. Theophylline was not prescribed. 
PROCEDURE 
Patients underwent a baseline multidimensional assessment 
exploring the following areas. 
l Sociodemographic area. Age, sex, years of formal educa- 
tion, smoking history (previous smoker, actual smoker), 
occupational role before retirement codified according to 
Featherman and Hauser (12) and marital status were 
recorded. 
*Functional capabilities. The performance in the Activities 
of Daily Living (ADLs) was directly observed by the 
examiner and not reported by the patient. ADLs are 
dressing, bathing, transferring, toileting, walking, eating 
(13). Each ADL performance was scored in a simplified 
form: 1, completely independent (performs by himself or 
herself); 0, performs with some help or is completely 
dependent on external help. Thus, the whole ADL score 
can range between 0 and 6. This simplified ADL score 
was adopted because it is expected to reduce the 
confounding effect of short-term changes in individual 
ability due to fluctuations in COPD severity. 
*Affective status. This was explored by the Geriatric 
Depression Scale (GDS). This self-administered question- 
naire includes 30 questions. Depressed subjects usually 
score 14 or more (14). 
l Cognitive function. This was assessed by the Mini Mental 
Status (MMS) test. This screening instrument, which is 
used worldwide, explores spatial and temporal orienta- 
tion, short-term and long-term verbal memory, attention, 
verbal attainment and praxic abilities. Normal subjects 
usually score 24 or more (15). 
@Medical area. Diseases were codified according to the 
International Classification of Health Problems in Primary 
Care (16). Charlson’s index of comorbidity was computed 
(17). This index provides a cumulative estimate of the 
burden of comorbidity which is known to affect the prog- 
nosis of homeliving patients with chronic diseases (18). 
@Respiratory function area. The forced vital capacity 
manoeuvre was performed by a Baires computerized 
system (Biomedin, Padova, Italy) according to guidelines 
provided by ATS in 1987 (19). Reference standards 
provided by Knudson et al. were used (20). Arterial blood 
gases were measured by a Radiometer ABL 330 
(Radiometer, Copenhagen, Denmark) with the patient at 
rest breathing room air from 1 h. 
l Nutritional area. Body mass index (weight in kg divided 
by the square of the of the height in m) was computed. 
Body weight was measured while the patient was fasting 
and without shoes and wearing light clothing. 
The assessment of cognitive and affective status and of 
functional capabilities and the measurement of arterial 
blood gas tensions were repeated yearly for two consecutive 
years. Alternative forms of questions of GDS and MMS 
were used, when available, to reduce the effect of practice 
on the performance. The assessor was unaware of the 
patient’s clinical conditions and respiratory function data 
as well as of results of previous assessments. The three 
assessments (baseline, 1 yr and 2 yr) of an individual patient 
were performed by different assessors (R.A.I., F.C., F.L.) in 
random order. 
STATISTICAL ANALYSIS 
The BMDP statistical package was used. 
COGNITIVE DECLINE IN COPD 529 
ccreened f~~ruitmeJ 
* 22 patients completed the 1 yr 
assessment before dying or 
being lost to follow-up 
FIG. 1. Partitioning of patients in groups and subgroups. 
Baseline characteristics of the 40 patients completing the 
2 yr follow-up (group A) were compared with those of the 
17 patients lost to follow-up (group B) and of the 27 
patients dead (group C). Differences between groups were 
assessed by the Yates-corrected x2 test for dichotomous 
data and by unpaired t test or Mann-Whitney test for 
continuous data with or without normal distribution and 
homogeneous variance, respectively (21). 
Changes in MMS, GDS and ADLs were assessed as 
follows: (1) by the Friedman’s ANOVA by rank test 
(baseline, 1 yr control, 2 yr control) in group A patients 
(22); (2) by the paired t test or Wilcoxon test, as appropri- 
ate, for group B and C patients performing the 1 yr 
assessment. The correlations between 2 yr changes in MMS 
(difference between 2 yr and baseline MMS scores) and the 
corresponding change of ADLs and GDS were assessed by 
Spearman’s p test (23). Patients completing the 2 yr 
follow-up were further divided into two subgroups depend- 
ing on whether their MMS score worsened (subgroup Al) 
or was unchanged or improved (subgroup A2). Differences 
in baseline characteristics between subgroups were assessed 
by parametric or non-parametric statistics, as appropriate. 
Results 
Figure 1 shows the partitioning of patients in groups and 
subgroups. Reasons for drop-outs were as follows: severe 
functional impairment preventing the patient from attend- 
ing the Pneumology outpatient department (seven cases); 
change of address and loss of any contact (four cases); 
moving to another country (three cases); lack of compliance 
with oxygen therapy (two cases); refusal of further care 
(one case). 
Table 1 compares the baseline characteristics of the 
groups with group A, i.e. the patients who completed the 
2 yr follow-up, as the reference group. Group B, which 
included patients who died before completing the follow- 
up, was characterized by better affective status and higher 
index of comorbidity than group A. Group C, i.e. patients 
lost to follow-up, had higher mean age and formal educa- 
tion than group A and more severe functional impairment, 
as reflected by the ADL score; a higher prevalence of 
comorbid diseases further characterized group C. Groups 
had comparable respiratory function data. The last finding 
shows that group A was representative of the whole COPD 
population selected for the study, at least with regard to the 
severity of respiratory function impairment. 
Table 2, upper part, summarizes results from Friedman’s 
ANOVA by rank test in group A. The MMS score 
decreased significantly from the first to the last assessment, 
while an incremental trend was evident for the GDS score. 
Given that the GDS score is directly proportional to the 
severity of depressive symptoms, these findings are consist- 
ent with a progressive deterioration of both cognitive and 
affective status. The worsening of MMS and GDS perform- 
ances was probably underestimated because the use of 
alternative forms for several questions cannot completely 
prevent the improvement in performance due to practice. 
ADLs declined non-significantly during the 2 yr study 
period. 
Table 2, lower part, compares baseline and 1 yr perform- 
ances on MMS, GDS and MMS of the 22 patients who 
underwent the 1 yr reassessment before dying or being lost 
to follow-up. A slight decline of cognitive and functional 
capabilities and a dramatic derangement of the affective 
status characterized these patients. 
A significant inverse correlation was found between 2 yr 
changes in MMS and in GDS scores @= - 0.32, P=O.O4). 
Thus, cognitive deterioration paralleled the worsening of 
the affective status. The correlation between 2 yr changes in 
MMS and ADLs scores was non-significant @= - 0.24, 
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TABLE 1. Baseline characteristics of the patients completing the 2 yr follow-up (group A), of the 
patients dead (group B) and of patients lost to follow-up (group C) 
Group A Group B Group C 
Number (males) 
Age (years) (mean f SD) 
Years of formal education (mean +Z SD) 
Low occupational role before retirement? (%) 
Actual smokers (%) 
MMS (mean f SD) 
ADLs (mean & SD) 
GDS (mean f SD) 
Body mass index (kg m - *) (mean * SD) 
FVC (% predicted) (mean & SD) 
FEV, (% predicted) (mean & SD) 
PaG, (kPa) (mean f SD) 
PaCG, (kPa) (mean f SD) 
pH (mean & SD) 
PA-a0, (kPa) (mean f SD) 
Charlson’s index of comorbidity (mean f SD) 
Prevalence of diabetes (%) 
Prevalence of hypertension (%) 
Prevalence of CAD-MI (%) 
Prevalence of renal failure (%) 
40 (33) 21 (22) 17 (9) 
68 f 9 68&11 73 f 9* 
6f3 7*4 9 f 3** 
57.5 51.8 29.4 
5 11.1 5.9 
27 f 2.9 26.7 f 3.9 26.3 f 3.4 
5.7 f 0.1 5.3 5 1.4 5.1 * 1.4* 
13.9 f 7.2 9.9 f 7.5* 10.3 f 9 
26.6 zk 4.2 25.4 f 5.9 27.2 f 5.5 
57.5 f 17.2 58.5 f 19.8 56.5 f 25.4 
33.2 f 18.8 34.6 zk 20.1 36.1 zt 19 
7.06 + 1 7.19 f 1.6 7.24 f 1 
6.8 + 1.2 7.01 f 1.4 6.68 * 1.2 
7.38 f 0.03 7.38 f 0.03 7.38 f 0.04 
4.85 f 1.1 5.97 f 3 5.30 + 2 
1.1 * 0.3 1.4 f 0.6* 1.5 f 0.6*** 
5 18.5 29.4** 
40 37 35.3 
10 22.2 11.8 
5 3.7 5.9 
FVC, forced vital capacity; FEV,, forced expiratory volume in 1 s; PA-aO,, alveolar-arterial oxygen 
difference; CAD-MI, coronary artery disease-myocardial infarction. 
The t test or Mann-Whitney test were used for comparing continuous data having or not having 
normal distribution and homogeneous variance, respectively; the 2 test was used for comparing 
dichotomous data. 
*P<O.O5 vs. group A; **P<O42 vs. group A; ***P<O.Ol vs. group A. 
TDefined according to Featherman and Hauser (11). 
P= - 0.13); on the average, functional capabilities 
decreased less than cognitive function. 
Table 3 compares baseline characteristics of subgroups 
Al and A2, i.e. of group A subjects whose MMS worsened 
(subgroup Al, n=23) or was unchanged or improved 
(subgroup A2, n= 17) after 2 yr. Patients at risk of cognitive 
decline were characterized by more severely depressed 
FEV, and FVC values, a tendentially lower occupational 
role before retirement and a significantly lower GDS score. 
Discussion 
This study provides the first demonstration that a close 
parallelism exists between cognitive decline and develop- 
ment of depressive symptoms in COPD patients. The 
combination of cognitive and affective symptoms is quite 
common in geriatric populations because patients with 
organic dementia frequently also become depressed, 
whereas primarily depressed subjects show cognitive 
changes severe enough to be referred to as dementia syn- 
drome of depression or pseudodementia (24,25). Pseudode- 
mentia is characterized by variable performance across 
similar tasks, impairment ‘of both recent and remote 
memory and frequently well-preserved attention and con- 
centration (25). The diagnostic protocol used by us lacks 
the potential for differentiating true dementia from depres- 
sive pseudodementia, which was out of the scope of the 
present study. However, the cognitive impairment pre- 
viously observed in COPD patients exempt from clinically 
relevant depression suggests that neuropsychological func- 
tion actually deteriorates in these patients (3). Given that 
depressive symptoms have recently been shown to herald 
dementia in the elderly, results from the present study might 
have different explanations (26). The only certain conclu- 
sion is that cognitive decline is more evident in patients 
whose affective status will shift from normality to 
depression. Thus, the onset of depression rather than 
its progression seems to be associated with faster 
cognitive decline. 
Loss of functional capabilities did not parallel the decline 
of neuropsychological functions. The observation by 
Similowski et al. that respiratory muscle strength at FRC 
level does not suffer from lung hyperinflation in patients 
with stable COPD provides a likely explanation for this 
finding: respiratory function at lung volumes needed for 
performing ADLs is relatively well preserved even in 
hypoxaemic COPD (27). Thus, functional impairment 
severe enough to affect performance on ADLs seems to be 
a very late event in the natural history of COPD. This might 
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TABLE 2. Changes of cognitive, functional and affective status in the 40 patients completing the 2 yr 
follow-up and in the 22 patients dead or lost to follow-up after completing the 1 yr assessment* 
Baseline 1 yr 2 yr P value 
Completed 2 yr follow-up 
MMS 21212.9 
ADLs 5.75 * 0.74 
GDS 13.3 & 7.2 
25.8 I!Z 4.1 25.4 i 4 0.0031 
5.65 * 0.95 5.6 f 1 0.317 
13.5 f 6.8 13.8 & 7.3 0.64t 
Dead or lost to follow-up after 1 yr 
MMS 27.6 zk 3 
ADLs 5.5 f 1.3 
GDS 11.9 it 8.8 
*Values expressed as mean & SD. 
26.2 f 3.6 0.051 
4.9 it 1.6 0.041 
14.5 =t I.6 0.002g 
tFriedman ANOVA by ranks test; .$Wilcoxon test. 
TABLE 3. Baseline characteristics of the 40 patients completing the 2 yr follow-up, subgrouped 
according to whether their MMS worsened (subgroup Al) or remained unchanged or improved 
(subgroup A2) 
Subgroup A 1 Subgroup A2 P value 
Number (males) 
Age (years) (mean f SD) 
Years of formal education (mean & SD) 
Low occupational role before retirement* (%) 
Actual smokers (%) 
MMS (mean & SD) 
ADLs (mean & SD) 
GDS (mean Z+ SD) 
Body mass index (kg m - ‘) (mean & SD) 
FVC (% predicted) (mean * SD) 
FEV, (% predicted) (mean f SD) 
Pa& (kPa) (mean f SD) 
PaCO, (kPa) (mean f SD) 
pH (mean rt SD) 
PA-a0, (kPa) (mean & SD) 
Charlson’s index of comorbidity (mean & SD) 
Prevalence of diabetes (%) 
Prevalence of hypertension (%) 
Prevalence of CAD-MI (%) 
Prevalence of renal failure (%) 
23 (21) 
66 f 8 
6~t2 
69.6 
4.3 
27.3 zt 3 
5.6 f 0.9 
11.9 * 7.7 
27.2 f- 3.9 
52.3 f- 17.1 
27.2 f 8.6 
6.94 zt 1.2 
7.10 f 1.1 
7.37 f 0.03 
4.65 zt 1.0 
1.13 * 0.3 
8.7 
34.8 
13 
4.3 
17 (12) 
70* 10 
753 
41.2 
5.9 
26.6 f 2.9 
5.9 f 0.2 
16.5 zt 5.6 
25.7 zt 4.5 
66.9 f 13.4 
44 f 26.8 
7.22 I!Y 0.9 
6.57 zk 1.3 
I.39 f- 0.03 
5.12 It 1.2 
1.06 •!= 0.2 
0 
47.1 
17.6 
5.9 
0.17t 
0.72t 
0.14f 
0.60% 
0.54t 
0.255 
0.04t 
0.28t 
0.03t 
0.09g 
0.57t 
0.17t 
0.07$ 
0.18t 
0.52t 
0.61; 
0.651 
0.52$ 
0.61$ 
FVC, forced vital capacity; FEV,, forced expiratory volume in 1 s; PA-O,, alveolar-arterial oxygen 
difference; CAD-MI, coronary artery disease-myocardial infarction. 
*Defined according to Featherman and Hauser (11). 
tt test; tx” test; §Mann-Whitney test. 
reflect different sensitivities of muscles and brain to hypo- 
xaemia and/or of ADL and MMS to mild variations in 
performance. The fact that patients had their hypoxaemia 
corrected and SaO,k90% does not exclude the former 
hypothesis because a wide range of actual PaO, and PaCO, 
values characterized the patient population. It remains to 
be defined whether functional impairment simply reflects 
the progressive deterioration of respiratory function or is 
partially attributable to cognitive and affective changes or 
to non-respiratory muscle wasting. This issue could not be 
clarified because functional decline prevented some of the 
patients from attending further the Pneumology outpatient 
department. 
Limitations of the present study are as follows. (1) Aging 
per se might partially account for the observed changes in 
cognitive and affective status. The lack of a control group 
of normal elderly prevents us from testing this possibility. 
However, age-related changes in select cognitive functions 
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become manifest over a very long time interval (28,29); 
accordingly, aging is unlikely to be the main determinant of 
changes recorded in a 2 yr period. Furthermore, the nega- 
tive trend of cognitive functions was probably smoothed by 
the practice effect. (2) Results from the present study apply 
to a COPD population with minimal or no signs of 
cognitive deterioration at baseline. Indeed, only seven 
patients had an MMS score inferior to 24. COPD patients 
with baseline cognitive impairment might experience a more 
severe neuropsychological involution. (3) We dealt with a 
selected COPD population regularly attending an out- 
patient Pneumology department and characterized by a 
high degree of compliance with oxygen therapy. A more 
negative trend of both affective and cognitive status is 
likely to occur in the overall COPD population having 
comparable baseline characteristics. 
These limitations do not weaken the main message from 
the present study: cognitive decline occurs even in COPD 
patients regularly performing oxygen therapy and is faster 
in subjects who belong to lower social class, have more 
severe bronchial obstruction and experience the onset of 
depressive symptoms. The possibility should be tested that 
the regular use of techniques of cognitive activation and 
occupational therapy, previously proven to slow cognitive 
decline in select geriatric populations (30) could benefit 
COPD patients at higher risk of mental deterioration. 
Future studies should also clarify how individual cognitive 
functions decline and contribute to the involution of overall 
cognitive performance. Finally, the possibility that depres- 
sion simulates cognitive decline in some patients deserves to 
be explored. Clarifying these issues would allow improve- 
ment of the management of COPD patients. Traditional 
management based on medical therapy and, at most, 
respiratory physiotherapy is unlikely to meet the needs of 
care of patients with such a broad and variegated burden of 
problems affecting quality of life. 
References 
1. Grant I, Heaton RK, McSweeney J, Adams KM, 
Timms RM. Neuropsychologic findings in hypoxemic 
chronic obstructive pulmonary disease. Arch Intern 
Med 1982; 142: 1470-1476. 
2. Heaton RK, Grant I, McSweeney J, Adams KM, Petty 
T. Psychologic effects of continuous and nocturnal 
oxygen therapy in hypoxemic chronic obstructive pul- 
monary disease. Arch Zntern Med 1983; 143: 1941-1947. 
3. Antonelli Incalzi R, Gemma A, Marra C, Muzzolon R, 
Capparella 0, Carbonin PU. Chronic obstructive pul- 
monary disease: an original model of cognitive decline. 
Am Rev Respir Dis 1993; 148: 418-24. 
4. Antonelli Incalzi R, Gemma A, Marra C, Capparella 
0, Fuso L, Carbonin PU. Verbal memory impairment 
in COPD: its mechanisms and clinical relevance. Chest 
in press. 
5. Cook NR, Evans DA, Scherr PA et al. Peak expiratory 
flow rate in an elderly population. Am J Epidemiol 
1989; 130: 66-78. 
6. Chyou P, White LR, Yano K et al. Pulmonary function 
measures as predictors and correlates of cognitive func- 
tioning in later life. Am J Epidemiol 1996; 143: 750-6. 
7. Dulfano MJ, Ishikawa S. Hypercapnia: mental changes 
and extrapulmonary complications. Ann Intern Med 
1965; 63: 829-41. 
8. American Thoracic Society. Standard for the diagnosis 
and care of patients with chronic obstructive pulmon- 
ary disease (COPD) and asthma. Am Rev Respir Dis 
1987; 136: 22544. 
9. Nocturnal Oxygen Therapy Trial Group. Continuous 
or nocturnal oxygen therapy in hypoxemic chronic 
obstructive lung disease. Ann Intern Med 1980; 93: 
391-398. 
10. American Psychiatric Association. Diagnostic and Stat- 
istical Manual of Mental Disorders, 3rd edition, revised. 
Washington, DC: American Psychiatric Association, 
1988. 
11. Consensus Conference. Differential diagnosis of 
dementing diseases. J Am Med Assoc 1987; 258: 
341 l-6. 
12. Featherman DL, Hauser RM. The measurement of 
occupation in social surveys. In: Hauser RM, 
Featherman DL, eds. The Process of StratiJication. 
New York: Academic Press, 1977, pp. 51-80. 
13. Katz S, Ford AB, Moskowitz RW, Jackson BA, 
Jaffe MW. Studies of illness on the aged. The index of 
ADL: a standardized measure of byological and 
psychosocial function. J Am Med Assoc 1963; 185: 
94-101. 
14. Yesavage J, Brink T, Rose T et al. Development 
and validation of a geriatric depression screening 
scale: a preliminary report. J Psychiatr Res 1983; 17: 
37-49. 
15. Folstein MF, Folstein SE, McHugh PR. ‘Mini Mental 
State’. A practical method for grading the cognitive 
state of patients for the clinician. J Psychiatr Res 1985; 
12: 189-198. 
16. Classification Committee of WONCA. Znternational 
Clas.@cation of Health Problems in Primary Care 
(ZCHPPC)-2-Defined, 3rd edition. Oxford: Oxford 
University Press, 1983. 
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A 
new method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. 
J Chron Dis 1987; 40: 373-83. 
18. Charlson M, Szatrowski TP, Peterson J, Gold J. 
Validation of a combine comorbidity index. J Clin 
Epidemiol 1994; 47: 1245-51. 
19. American Thoracic Society. Standardization of spirom- 
etry: 1987 update. Am Rev Respir Dis 1987; 136: 
1286-1296. 
20. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. 
The maximal expiratory flow-volume curve. Normal 
standards, variability, and effects of age. Am Rev Respir 
Dis 1976; 113: 587-600. 
21. Mann HB, Whitney DR. On a test of whether one of 
two variables is stochastically larger than the other. 
Ann Math Stat 1947; 18: 50-60. 
COGNITIVE DECLINE IN COPD 533 
22. Friedman M. The use of ranks to avoid the assumption 
of normality implicit in the analysis of variance. J Am 
Stat Assoc 1937; 32: 675-701. 
23. Olds EG. The 5% significance levels for sums of squares 
of rank differences and a correction. Ann Math Stat 
1949; 20: 117-8. 
24. McAllister TW, Price TRP. Severe depressive pseudo- 
dementia with and without dementia. Am J Psychiatry 
1983; 140: 528-533. 
25. Wells CE. Pseudodementia. Am J Psychiatry 1979; 136: 
8955900. 
26. Speck CE, Kukull WA, Brenner DE et al. History of 
depression as a risk factor for Alzheimer’s disease. 
Epidemiology 1995; 6: 366-9. 
27. Similowski T, Yan S, Gauthier AP, Macklem PT, 
Bellemare F. Contractile properties of the human dia- 
phragm during chronic hyperinflation. N Engl J Med 
1991; 325: 917-23. 
28. Hertzog C, Schaie KW. Stability and change in adult 
intelligence: 1. Analysis of longitudinal covariance 
structures. Psycho1 Aging 1986; 1: 159-171. 
29. Hertzog C, Schaie KW. Stability and change in adult 
intelligence: 1. Simultaneous analysis of longitudinal 
means and covariance structures. Psycho/ Aging 1988; 
3: 122-130. 
30. Treat NJ, Poon LW, Fozard JL. Age, imagery, and 
practice in paired-associated learning. Exp Aging Res 
1981; 7: 33742. 
